Page 34 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $3.95
52wk Low $0.65 IN8bio, Inc. INAB $1.04
350 5th Avenue
New York, NY 10118

(USD - in millions) in8bio.com
Market Cap 48.0
Enterprise 31.7
Basic Shares Out. 43.29 COMPANY OVERVIEW
Float 24.46
Institutional Holdings 22.12% Detailed Analysis:Channelchek.com
Short Interest 0.05
Avg. 90-Day Volume 0.34 IN8bio is a clinical-stage biopharmaceutical company developing
gamma-delta T cell-based immunotherapies for cancer patients.
Gamma-delta T cells are a specialized population of T cells that
possess unique properties, including the ability to differentiate between
EPS Data healthy and diseased tissue. The company’s lead program, INB-400, is
in a Phase 2 trial in glioblastoma multiforme (GBM). Additional
2021 2022 2023 programs include Phase 1 trials in solid and hematologic tumors,
CQ1 N/A (0.33) (0.30) including INB-200 for GBM and INB-100 for patients with hematologic
CQ2 (1.00) (0.38) (0.27) malignancies undergoing transplantation.

CQ3 (0.25) (0.34) (0.23)
CQ4 (0.21) (0.31) (0.21)
CY (1.47) (1.36) (1.00) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.58
ROE (ttm) -125.90
Debt-to-Total Cap. (mrq) 16.40
Fiscal Year End 31-Dec
350 5th AvenuNew York NY 10118

Key Executives
CEO: Ho, Tai-Wei
CFO: McCall, Patrick
COO: Rochlin, Kate
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures